Molecular Partners AG - Asset Resilience Ratio

Latest as of September 2025: 19.76%

Molecular Partners AG (MOLN) has an Asset Resilience Ratio of 19.76% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Molecular Partners AG working capital to net assets to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

CHF22.16 Million

≈ $28.02 Million USD Cash + Short-term Investments

Total Assets

CHF112.15 Million

≈ $141.79 Million USD All company assets

Resilience Assessment

Good

Financial Resilience Level

Asset Resilience Ratio Trend (2015–2024)

This chart shows how Molecular Partners AG's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see how large is Molecular Partners AG's balance sheet.

Liquid Assets Composition Over Time

This chart breaks down Molecular Partners AG's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read debt load of Molecular Partners AG for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CHF0.00	0%
Short-term Investments	CHF22.16 Million	19.76%
Total Liquid Assets	CHF22.16 Million	19.76%

Asset Resilience Insights

Good Liquidity Position: Molecular Partners AG maintains a healthy 19.76% of assets in liquid form.
This level provides good financial flexibility while maintaining productive asset deployment.
The company has significant short-term investments, indicating active treasury management.

Molecular Partners AG Industry Peers by Asset Resilience Ratio

Compare Molecular Partners AG's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Tubize-Fin BR:TUB	Biotechnology	2.50%
Dianthus Therapeutics Inc. NASDAQ:DNTH	Biotechnology	63.98%
Tango Therapeutics Inc NASDAQ:TNGX	Biotechnology	62.24%
Damora Therapeutics, Inc. NASDAQ:DMRA	Biotechnology	0.00%
Wecome Pharmaceutical Co Ltd SHE:300878	Biotechnology	0.67%
Tectonic Therapeutic, Inc. NASDAQ:TECX	Biotechnology	86.66%
Relmada Therapeutics Inc NASDAQ:RLMD	Biotechnology	95.25%
MediWound Ltd F:M8W	Biotechnology	56.04%

Annual Asset Resilience Ratio for Molecular Partners AG (2015–2024)

The table below shows the annual Asset Resilience Ratio data for Molecular Partners AG.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	53.97%	CHF85.56 Million ≈ $108.18 Million	CHF158.53 Million ≈ $200.42 Million	-6.31pp
2023-12-31	60.29%	CHF119.58 Million ≈ $151.18 Million	CHF198.35 Million ≈ $250.77 Million	-1.18pp
2022-12-31	61.47%	CHF161.20 Million ≈ $203.80 Million	CHF262.26 Million ≈ $331.56 Million	+26.14pp
2021-12-31	35.33%	CHF61.00 Million ≈ $77.12 Million	CHF172.67 Million ≈ $218.30 Million	+14.00pp
2020-12-31	21.33%	CHF40.00 Million ≈ $50.57 Million	CHF187.55 Million ≈ $237.11 Million	+2.87pp
2019-12-31	18.46%	CHF19.37 Million ≈ $24.49 Million	CHF104.94 Million ≈ $132.67 Million	--
2018-12-31	0.00%	CHF0.00 ≈ $0.00	CHF155.16 Million ≈ $196.16 Million	--
2017-12-31	6.75%	CHF9.74 Million ≈ $12.32 Million	CHF144.42 Million ≈ $182.59 Million	-9.81pp
2016-12-31	16.56%	CHF30.49 Million ≈ $38.55 Million	CHF184.10 Million ≈ $232.75 Million	+7.44pp
2015-12-31	9.13%	CHF20.02 Million ≈ $25.31 Million	CHF219.40 Million ≈ $277.38 Million	--

pp = percentage points

About Molecular Partners AG

SW:MOLN Switzerland Biotechnology

Market Cap

$163.60 Million

CHF129.40 Million CHF

Market Cap Rank

#17854 Global

#181 in Switzerland

Share Price

CHF3.46

Change (1 day)

+6.46%

52-Week Range

CHF2.75 - CHF3.95

All Time High

CHF38.40